| Date | Title | Description |
| 14.08.2024 | Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep | Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep
Wed, Aug 14, 2024 08:30 CET Report this content
• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoi... |
| 29.11.2023 | Flagship Pioneering crosses the pond, opens a European front | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the latest twist for a futuristic cancer therapy, big money for longevity r... |
| 05.05.2023 | Drug Developer Acelyrin Raises $540 Million in IPO | Drugmaker Acelyrin has raised $540 million through an initial public offering despite a chilly market for biotechnology companies seeking to make their stock-market debuts.
Acelyrin, based in the Los Angeles area, issued 30 million shares a... |
| 08.11.2022 | Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022 | Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022
Tue, Nov 08, 2022 17:07 CET Report this content
• Izokibep P... |
| 13.09.2022 | Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials | ... |
| 13.09.2022 | Acelyrin Raises $300M Series C Financing | Acelyrin, a Los Angeles, CA-based late-stage clinical biopharma company, raised $300M in Series C funding.
The round was led by Access Biotechnology with participation from existing investors AyurMaya – an affiliated fund of Matrix Capital ... |
| 13.09.2022 | Acelyrin scores series C that brings total raised in less than a year past $500M | Any biotech that can rake in half a billion dollars from investors in 12 months is clearly doing something right. The $300 million series C funding round Acelryin announced this morning means the inflammatory-disease-focused drug developer ... |
| 13.09.2022 | ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases | - |
| 03.06.2022 | Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress | Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress
Fri, Jun 03, 2022 11:15 CET Report this content
• Data suggest... |
| 14.12.2021 | Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis | Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Tue, Dec 14, 2021 11:03 CET
SOLNA, Sweden, LOS ANGELES, Calif., and SHANGHAI, China, Dece... |
| 16.11.2021 | Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties | Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties Tue, Nov 16, 2021 15:20 CET
Solna, Sweden, November 16, 2021. Affibody AB today announced ... |
| 16.11.2021 | ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases | LOS ANGELES, Nov. 16, 2021 /PRNewswire/ -- ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, today announced the compl... |
| 16.11.2021 | Casper turns painful even for some of its earliest startup investors | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Even if a startup takes a cut to its valuation, it’s completely possible that investors who took ... |
| 16.11.2021 | Acelyrin Wants to Move LA Biotech Beyond the 'Innovate and Exit' Model | The reality for most bioscience startups developing drugs is that, if they don't fail, they will be swallowed up by a pharmaceutical giant.
After a decade in the pharmaceutical industry and being involved in developing several high-profile ... |
| 16.11.2021 | ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases | - |
| 10.06.2021 | ACELYRIN Announces Appointment of Patrick Machado, JD to Board of Directors | |
| 17.02.2021 | Westlake Village BioPartners Names New Chief Operating Officer | Westlake Village BioPartners, the two-year-old venture capital firm founded by former Amgen executives and focused on bioscience startups named Peter Calveley its chief operating officer on Wednesday.
A former executive at health care indus... |
| 16.12.2020 | New Biopharma Company Acelyrin Is on the Hunt for Immunotherapy Drugs | A new biopharmaceutical startup, ACELYRIN, that launched this week is on the hunt for new immunological therapies that it can bring to market.
The company just closed a round backed by Westlake Village BioPartners, a two-year-old venture ca... |
| 15.12.2020 | Horizon alums unveil Acelyrin, a biotech to accelerate the development of promising drugs | Acelyrin CEO Shao-Lee Lin, M.D., Ph.D.
(Acelyrin)
Shao-Lee Lin, M.D., Ph.D., and Bob Carey didn’t leave Horizon Therapeutics with explicit plans to team up later on. But, as they got talking about what their next chapters could be, they rea... |
| 15.12.2020 |
ACELYRIN Snags Funding For Biotech Effort
| Los Angeles-based ACELYRIN, a new startup biopharma company, announced this morning that it has raised a Series A funding. Size of the funding round was not announced. The funding came from Westlake Village BioPartners. ACELYRIN said it is ... |
| 15.12.2020 | Venture Capital Firm Westlake Village BioPartners Raises $500M | Westlake Village BioPartners, the two-year-old Los Angeles venture capital firm investing in life science and therapeutic companies, has raised two new funds totaling $500 million. The announcement Tuesday brings the firm to $820 million in... |
| - | ACELYRIN | “Building a sustainable biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines.” |
| - | Rivian Surprises Many As Q1 Earnings Outperform EV Competitors | This is the web version of dot.LA’s daily newsletter. Sign up to get the latest news on Southern California’s tech, startup and venture capital scene.
It’s earnings season, baby! I feel like we just did this, but four quarters in a year mea... |
| - | Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds | Nearly a year ago, biotech startup Acelyrin emerged with two industry veterans at the helm, an unspecified amount of funding, and plans to in-license drug candidates with an initial focus on immunology. The company played its cards close to... |
| - | There’s No Real Plan for Preserving Internet Content. Here’s Why That’s a Problem | Back in April, image hosting site Imgur – a popular option for users of Reddit and similar forums seeking to post memes or photos – announced a sweeping change to its Terms of Service. As of May 15, the site will no longer host “nudity, por... |
| - | How Acelryin Achieved One of Biotech's Largest IPO's to Date | Woodland Hills-based clinical biopharmaceutical company Acelyrin went public on the NASDAQ markets May 5, securing one of Los Angeles’ most valuable initial public offerings in two years.
The IPO priced Acelyrin’s 34.5 million shares at $18... |
| - | With AI and Biosensors, Sensydia Hopes To Revolutionize Heart Disease Screening | More than 6 million U.S. adults are currently living with heart failure. By 2030, that number is expected to climb to nearly 8 million.
Currently, the way to test for heart failure is a painstaking process known as cardiac catheterization.
... |
| - | How Nex Cubed is Helping to Level the Playing Field by Promoting Diversity in Tech | Black founders have historically been at a disadvantage when it comes to accessing funding. Only 2% of VC dollars each year reach the hands of black founders and in 2022, they saw even less with a 45% decrease in funding.
Nex Cubed, a San D... |
